EYEN has a pioneering precision ophthalmology dosing technology that could disrupt eye droppers.
Lead program is a treatment for closed angled glaucoma that will enter Ph3 Q1/19
EYEN is expecting data in 2019 for their pharmacologic dilation program.
They have an OTC artificial tears device that may be ready to market in 2019.
Their program with the greatest commercial potential is their treatment to arrest Myopia. It's entering the clinic in 2019 and is expected to be ready for regulatory submission ins 2022.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.